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Transient thrombocytopenia in association with
the administration of heparin was first identified in
animals in 19421 and in humans in 1962.2 Throm-
boembolic sequelae during heparin therapy was
described in 1958.3 However, the relationship
between heparin-induced thrombocytopenia (HIT)
and thromboembolic complications was not report-
ed until 1973.4
HIT syndrome is an idiosyncratic autoimmune
disorder that occurs in 1% to 3% of patients who
receive heparin. Heparin-associated antiplatelet anti-
bodies (HAAb) developed in patients and activated
platelets in the presence of heparin and releasable
platelet proteins (e.g., platelet factor IV). The
platelet activation may result in platelet aggregation
with thrombocytopenia and arterial or venous
thrombosis. Bleeding results in approximately 5% of
patients, especially those with low platelet counts.
We presented a review of morbidity and mortal-
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ity data of HIT in 62 patients in 1983. Thirty-eight
of the 62 patients (61%) had thromboembolic or
hemorrhagic complications caused by the adminis-
tration of heparin. Fourteen deaths (23%) were
related to the administration of heparin.5 A 1987
follow-up study, during which 169 patients with
HIT from the prior 3-year period were reviewed,
reported a substantial reduction in morbidity and
mortality rates.6 Thromboembolic or hemorrhagic
complications were present in 38 of the 169 patients
(23%), and death occurred in 21 patients (12%). The
marked reduction in morbidity and mortality rates
was attributed to earlier recognition of the disorder,
immediate cessation of the administration of
heparin, and institution of platelet function inhibi-
tion.
The goal of the present study was to determine
whether aggressive screening and prompt manage-
ment had led to further reductions of the morbidity
and mortality rates.
METHODS
We reviewed the charts of 100 patients who con-
secutively had tested positive for HAAb determined
by platelet aggregation. The following data were
reviewed: age; gender; heparin type, route, amount,
and indication for therapy; platelet counts; manage-
ment; complications; and deaths. The study was
approved by the Institutional Review Board of the
University of Missouri–Columbia.
Our method of platelet aggregation testing for
HAAb has been discussed in detail.7 A review of the
method follows. Platelets are obtained from a select
pool of normal donors (normal platelet count, no
antiplatelet therapy for 14 days). The patient’s
platelet-poor plasma (0.015 ml) is sequentially
mixed with the normal donor’s platelets (0.1 ml)
and low-dose heparin (0.025 ml of 10 U/ml, final
heparin concentration of 1 U/ml). If aggregation
does not occur, adenosine diphosphate (ADP 10-4
mol/L) is used to stimulate platelet activity and to
ensure the platelets are reactive. If aggregation does
occur, the plasma is retested with high-dose heparin
(0.025 ml of 1000 U/ml, final concentration of 100
U/ml) to eliminate false-positive results caused by
nonspecific binding between heparin and platelets.8
Platelet aggregation is detected with a platelet
aggregometer (Chronolog Corp., Haverton, Pa.).
Lag time, slope of the aggregation curve, and time
to aggregation are recorded. A positive platelet
aggregation result is assigned to tests with a 20% or
greater increase in optic density. Aggregation is con-
firmed by visual inspection.
HIT was suspected in all patients who received
heparin and in whom any of the following symptoms
developed: falling platelet count, platelet count less
than 100,000/mm3, or new thromboembolic or
hemorrhagic complications. Patients with a history of
HAAb were retested on readmission to the hospital.
Treatment consisted of prompt cessation of
heparin therapy or alternative forms of anticoagula-
tion therapy (i.e., low molecular weight heparins
(LMWHs), antiplatelet agents, warfarin), or both as
dictated by the patient’s disorder. Patients with
known HAAb were not offered heparin, or they
were treated with preoperative platelet function
inhibition and a limited reexposure to heparin (1
dose) during surgery.
Deaths were attributed to the HIT syndrome
when caused by thrombotic, embolic, or hemor-
rhagic sequelae in patients who were receiving
heparin. Sixteen deaths occurred because of the
patient’s primary disease and were not directly relat-
ed to thromboembolic complications of HIT.
RESULTS
Platelet aggregation studies identified HAAb in
100 patients between May 10, 1993, and June 5,
Table I. Patients without complications (n = 87*)
Service Vascular Cardiothoracic Other
Heparin
U/day (mean range) 10 to 28,000 880 to 27,200 10 to 38,300
Mean days (range) 5.4 (1 to 24) 2.5 (1 to 8) 8.2 (1 to 34)
Average platelet counts 
(· 103/mm3)
Admission 225 232 215
Nadir 114 131 108
Final count 198 181 206
*Six patients with HAAb did not receive heparin.
1996. Sixty-six patients were male and 34 were
female. Their ages ranged from 23 days to 92 years.
Patients without complications (Table I). Six
patients, with known HAAb from previous heparin
exposures, retested positive for HAAb. These six
patients were not reexposed to heparin and therefore
were not at risk for heparin-induced complications.
These six patients are excluded from Table I.
Twelve cardiothoracic patients had known
HAAb from previous heparin exposure and had
repeat positive platelet aggregation test results. All
12 patients received preoperative platelet function
inhibition with aspirin (325 mg/day) and a limited
reexposure (1 dose) to heparin during coronary
artery bypass grafting (average, 1545 U of beef
heparin). Heparin-related complications did not
develop in any of the 12 patients.
The remaining 75 of the 87 patients who
received heparin without complications were man-
aged with prompt cessation of heparin therapy.
These patients received between 10 and 38,300
units of heparin daily. The heparin was administered
as flushes to maintain patency of intravenous
catheters, as thromboembolic prophylaxis in the
postoperative period, during dialysis, during opera-
tion for vascular procedures or coronary bypass, and
intravenously for management of thrombotic disor-
ders (e.g., deep venous thrombosis, pulmonary
embolus, unstable angina, new onset atrial fibrilla-
tion).
Thrombocytopenia developed in fifty-four of the
87 patients who received heparin (platelet count <
100,000/mm3), and 33 patients never had platelet
counts below 100,000/mm3. The duration of
heparin administration ranged from 1 day to 34
days.
Of the 87 patients without complications, 43
patients were treated with platelet function inhibi-
tion (aspirin, dipyridamole, or both), 13 patients
received warfarin, 17 patients had platelet function
inhibition (aspirin, dipyridamole, or both) and war-
farin, and 11 patients had no specific therapy during
hospital courses. Enoxaparin (LMWH) was used
successfully in three patients after platelet aggrega-
tion testing determined no cross-reactivity to the
HAAb from unfractionated heparin.
Patients with complications. Seven patients
had 11 (10 thromboembolic and 1 hemorrhagic)
HIT-related complications (Table II). Three of the
seven patients were managed successfully without
operations. Warfarin and aspirin (325 mg/day) were
used in two of the three patients and aspirin alone
was used (325 mg/day) in the other patient. The
remaining four patients required surgery and med-
ical management.
All seven patients had had previous heparin
exposure but had never been tested previously for
HAAb. Patients 1, 2, 3, 5, 6, and 7 had complica-
tions after antiplatelet therapy and a prolonged reex-
posure (mean, 8.5 days; range, 2 to 30 days) to
heparin. Patient 4 received platelet function inhibi-
tion and a limited reexposure to heparin.
Administration of heparin was discontinued for
patients 2 and 6 before the establishment of a defin-
itive diagnosis by the platelet aggregation test. In
patients 1 and 3, heparin administration was stopped
the day of a positive platelet aggregation test. In
patient 5, heparin was discontinued 2 days after a
positive platelet aggregation test. The only death
occurred in patient 7, who received heparin for 30
days after a positive platelet aggregation test.
One bleeding complication occurred in patient
1. Platelet counts less than 100,000/mm3 devel-
oped in three of the seven patients. The mean nadir
for the group was 117,000/mm3.
Six of the seven patients, patient 6 excluded,
were receiving aspirin (dose ranged from 81 to 325
mg/day) at the time of their complications. Patient
6 was receiving dextran 40 at 10 ml/hour at the
time of his complication. The thrombotic complica-
tions of patients 3, 4, 5, and 6 were managed with
warfarin anticoagulation.
DISCUSSION
HIT presents in two forms. The more common
type I occurs 2 to 3 days after the initiation of
heparin therapy.1 The thrombocytopenia is tran-
sient, and its sequelae are clinically insignificant.
Type I HIT occurs in as many as 15% of patients
exposed to heparin.9 Type II HIT occurs in 0.9% to
31% (usually 1% to 3%) of patients who receive
heparin and is frequently associated with life-threat-
ening or limb-threatening thromboembolic compli-
cations.
The pathophysiology of type II HIT results from
the development of heparin-associated antiplatelet anti-
bodies. These IgG and IgM, rarely IgA, antibodies are
specific for epitopes on the heparin molecule. Recent
evidence suggests that the immune complex formation
also requires platelet factor 4 or other releasable platelet
proteins.10-12 These antibodies, in the presence of
heparin and the immune complex, induce platelet
aggregation. The thrombocytopenia and thrombotic
complications associated with the HIT syndrome result
from the platelet activation and aggregation.
Several laboratory assays are available for detect-
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ing the presence of HAAb. The authors and others
have obtained a sensitivity with platelet aggregome-
try that ranges from 88% to 100%.13 Other less
widely used assays include the platelet 14C-serotonin
assay, platelet factor 3 availability assay, compliment
fixation, and hemagglutination assays.
All patients who receive heparin are at risk for
HIT. No known patient characteristics predict the
development of this syndrome. Patient sensitization
is not related to the heparin dose. HIT can occur in
patients who receive small amounts of heparin (i.e.,
heparin flushes for intravenous catheters or heparin
coated central catheters).14 Patients of all ages,
including newborns, are at risk for becoming sensi-
tized by heparin.15 The route of administration does
not seem to alter this risk. HIT has been described
in patients who receive pork and beef heparins and
LMWHs.
The paradoxical thromboembolic complications
associated with HIT can be prevented if the charac-
teristic thrombocytopenia is recognized early and
the administration of heparin promptly discontin-
ued. After thromboembolic complications occur,
cessation of heparin therapy is essential to successful
management. Continued heparin administration is
associated with progression of thrombocytopenia
and related complications. Kapsch and Silver7
reviewed 31 patients with HIT and reported avoid-
ance or remission of the thromboembolic complica-
tions and immediate improvement of the thrombo-
cytopenia with cessation of heparin administration.
Bleeding complicates 5% of HIT cases. We rarely
offer platelet transfusions to patients with platelet
counts higher than 20,000/mm3. Platelet transfu-
sions are reserved for the thrombocytopenic patients
who develop bleeding complications. Hematomas
are drained surgically as needed.
Although the initial sensitization to heparin
occurs between 5 and 14 days of heparin therapy,
thrombocytopenia and thrombosis can occur on the
Table II, A. Profiles of patients with complications (n = 7)
Diagnosis/procedure Complication Heparin dose*
Patient 1    CEA Thrombosis RICA, Intraoperative
neck hematoma
Patient 2    CABG, 80% RICA CVA Continuous IV
Patient 3    CABG Thrombosis LIMA Intraoperative
and SVG
Patient 4    CABG Calf vein thrombosis, Continuous IV
PE
Patient 5    Splenic infarct PE Continuous IV
Patient 6    Dialysis Thrombosis AVG (· 2) During dialysis
Patient 7    MI, CABG Thrombosis AVG (· 2), During dialysis
cerebellar infarct
*All patients were previously exposed to heparin.
Table II, B. Management of patients with complications (n = 7)
Antiplatelet therapy Management Outcome
Patient 1 Aspirin before and after surgery Thrombectomy, drainage Discharged to 
of hematoma, aspirin rehabilitation
Patient 2 Aspirin before and after surgery Aspirin Discharged to 
rehabilitation
Patient 3 Aspirin before and after surgery Angioplasty/thrombolysis, Discharged home
warfarin
Patient 4 Aspirin before and after surgery Warfarin Discharged home
Patient 5 Aspirin during hospital course Warfarin Discharged home
Patient 6 Dextran 40 Thrombectomy · 2, Peritoneal dialysis
warfarin
Patient 7 Aspirin before and after surgery Thrombectomy · 2 Multisystem organ failure, 
died
CEA, carotid endarterectomy; RICA, right internal carotid artery; IV, intravenous catheter; CABG, coronary artery bypass grafting;
CVA, cerebrovascular accident; LIMA, left internal mammary artery; SVG, saphenous vein graft; PE, pulmonary embolus; AVG, arterio-
venous graft; MI, myocardial infarction
first day of reexposure to heparin. Previous heparin
exposure within 2 months in susceptible persons
may hasten the occurrence of thrombocytopenia and
development of thromboembolic complications.16
The interval from the time of heparin reexposure to
thrombocytopenia/thrombosis can be just hours, as
in patients 1 and 3 of the complication group.
Antiplatelet therapy, given before a limited reex-
posure to heparin, protected patients who under-
went coronary bypass grafting from thromboembol-
ic complications in a previous report.17 In the cur-
rent review, 12 cardiothoracic patients were
successfully managed with preoperative antiplatelet
therapy and a limited reexposure to heparin. One
cardiothoracic patient managed with this approach
(patient 4; Table II), however, had a thrombotic
complication after surgery.
Five of the seven patients with complications
were receiving aspirin during the prolonged reexpo-
sure (average 8.5 days) to heparin. In dialysis,
patient 6 received dextran 40 during reexposure to
heparin. This patient twice had thrombosis after
dialysis of his arteriovenous graft. The two
thrombectomies failed, and the patient subsequent-
ly was converted to peritoneal dialysis.
Platelet counts should be obtained before the
initiation of heparin therapy in any patient and
obtained daily during the time of heparin adminis-
tration for all patients with prior exposure to
heparin. If the patient has not had prior exposure,
platelet counts can be initiated on the fourth day of
heparin therapy. Any patient who receives heparin
and has an unexplained decrease in platelet count
may have the HIT syndrome. We stop heparin ther-
apy and test all patients with falling platelet counts
for antibodies. In the past, a 30% drop in the platelet
count was significant. Currently, any decrease in the
platelet count is significant.
Development of thrombocytopenia has been
considered a prerequisite for thrombotic and hem-
orrhagic complications, but recent reports have
described patients with HIT-related thromboses
despite normal platelet counts.18 Four of seven
patients in the complication group in this review had
platelet counts greater than 100,000/mm3 at the
time of complication. Only 54 of the 87 patients
who did not develop complications had platelet
counts that fell below 100,000/mm3.
Demasi et al.19 reviewed data from 10 patients
with HIT. They reported an 80% morbidity rate (all
thromboembolic complications) and a 30% mortali-
ty rate. They recommended immediate cessation of
all exposure to heparin and institution of warfarin in
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patients who required anticoagulation therapy.
Other suggestions included use of antiplatelet thera-
py with aspirin and dextran 40 while awaiting full
oral anticoagulation and platelet aggregation testing
for patients with previous HIT who require cardiac
or vascular surgery. They recommended that, with
positive tests, elective procedures be delayed and
repeat testing performed in several months because
some patients will subsequently have a negative test
result. In urgent situations, they recommend preop-
erative antiplatelet therapy (aspirin and dipyri-
damole) and heparin exposure limited to a single
intraoperative dose.
AbuRahma et al.20 reported 12 patients with
white clot syndrome; 50% had thromboembolic
complications and 25% died. They recommended
frequent monitoring of platelet counts for patients
on heparin therapy and discontinuance of heparin if
HIT was suspected. They advocated the use of anti-
aggregating agents (e.g., dextran 40) to increase the
platelet count and noted their importance in the
treatment of HIT.
We reported morbidity and mortality rates of
61% and 23%, respectively, in patients with HIT in
1983. With early recognition and treatment, the
morbidity and mortality rates were reduced to 23%
and 12%, respectively, in 1987. In the current series,
the morbidity and mortality rates are 7.4% and 1.1%,
respectively. The changes in management consist of
the following differences: earlier withdrawal of
heparin when any decrease (not just a 30% decrease)
in platelet count is observed, testing all patients with
a decrease in platelet count for HAAb, use of
LMWHs in patients whose HAAb do not cross-react
with LMWHs, using platelet function inhibition and
a limited reexposure of heparin (1 dose) during
surgery in patients with HAAb who underwent
urgent vascular or cardiothoracic surgery, retesting
all patients with a history of HAAb for platelet
aggregation and abstinence from heparin if they test
positive, and earlier withdrawal of heparin with use
of alternate anticoagulant agents when indicated.
The most important aspect of management of
HIT is prompt discontinuation of heparin. If our
patients require heparin-like anticoagulation therapy
and platelet aggregation studies demonstrate no
cross-reactivity with unfractionated heparin,
LMWHs are used. We successfully treated three
patients in this series with enoxaparin and subse-
quently successfully treated three other patients with
the same. More than 66% of patients with HAAb
will not cross-react to enoxaparin,21 and 74% will
not cross-react to dalteparin.22 If the LMWH caus-
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es platelet aggregation and heparin-like anticoagula-
tion therapy is required, we consider blocking the
platelet glycoprotein IIb/IIIa receptor with a mon-
oclonal antibody23 or alternatively using a heparin
substitute. A few patients with HIT have been treat-
ed with heparin substitutes (i.e., LMWHs,21 hepari-
noids,24 hirudin,25 ancrod).26,27
Other strategies of management include delaying
elective vascular and cardiothoracic surgery cases
until HAAb titers are nondetectable and testing all
patients who have had previous heparin exposure for
the presence of HAAb before instituting heparin
therapy.
The morbidity and mortality rates of our patients
have markedly improved since our first report in
1983.5 In the current series, the morbidity and mor-
tality rates have fallen to 7.4% and 1.1%, respective-
ly. Decreased morbidity and mortality rates have
resulted from early diagnosis of HIT with prompt
cessation of patient exposure to the sensitizing
heparin.
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Dr. Michael Sobel (Richmond, Va.). I congratulate
Dr. Almeida for a fine presentation and for carrying on the
long tradition established by Dr. Donald Silver and his
group. Almost 25 years ago, Dr. Silver first published his
seminal observations of paradoxical thrombosis associated
with heparin therapy. In the intervening time, we have
learned much about the pathophysiologic mechanism of
the syndrome. The disease has a wide spectrum of mani-
festations and severity. Like other immune syndromes,
such as lupus, the disease can range from an asymptomatic
positive serology to a florid immunologic syndrome with
fatal end-organ complications. Of all patients exposed to
heparin, the largest portion will develop antibodies that
recognize this complex antigen of heparin and platelet fac-
tor IV. This portion is probably much larger than we have
ever known. The group may include a quarter to half of all
patients who undergo PTCA or cardiopulmonary bypass
grafting, but most of these patients are asymptomatic.
Thus the clinical significance of the presence of the anti-
body alone is still moot.
A smaller subset of patients with antibodies may also
have a drop in their platelet count or show positive platelet
aggregation testing, perhaps 1% to 5%. Many of these
patients will also remain asymptomatic except for a drop in
their platelet count. The smallest group consists of those
patients in whom more severe thrombocytopenia and clin-
ical thromboses develop. This group is probably fewer
than 1% of all patients who are heparinized.
Why do some groups have more severe manifestations
than others? The degrees of manifestation may be related
both to antibody titers and some genetic variability in the
platelets receptor for antibodies.
In your manuscript, the population included many
patients from this larger universe of patients who are
asymptomatic or nearly asymptomatic, and mildly affect-
ed. In any disease, the more intensely you look, the more
likely you are to encounter subclinical or even clinically
insignificant disease. For example, the average nadir of the
platelet counts in your summary data was 100,000. So the
first lesson I draw is that a high index of suspicion, early
recognition, and action may interrupt the progression to
more severe manifestations of the disease.
I have some specific questions about how you define
complications. A dropping platelet count was considered
an indication for investigation. Warkentin and his Canadi-
an colleagues have recommended a rigorous numeric for-
mula for defining what the drop of platelet count should
be. What was your definition? You mentioned complica-
tions without defining them. What is a complication from
HIT and what is not?
Finally, your categorization of deaths was of concern
to me. In the surgical literature, all deaths are customarily
included in mortality statistics. For example, if you are
looking at carotid endarterectomy or aneurysm surgery,
you count every death in the study population even if you
are unsure whether you can blame the death on the
surgery. In your group of 100 patients, 17 patients died,
resulting in a fairly large mortality rate. In this syndrome
of HIT, how the immunologic syndrome might have
affected the mortality rate of the patients is often difficult
to define. I suggest that you give more details about these
other deaths, and let us decide the cause ourselves.
The clinical lessons from your review still remain clear
and strong. A high index of suspicion for HIT, liberal test-
ing, immediate cessation of heparin, and use of alternative
antithrombotic agents will give us the good results you
have had.
Dr. Jose Almeida. Your first question addresses the
nadir of the patients who were thrombocytopenic. We
have not strictly defined what percentage drop in platelet
counts is significant in this series. In the literature, one
sees a range from 30% to 40% drop in platelet counts. We
use a high index of suspicion and a dropping platelet
count; we then stop heparin therapy and send a plasma
sample for a heparin antibody test. In fact, 43% of the
patients in this study were not thrombocytopenic below
100,000/mm3. I think the message here is early cessation
of heparin therapy allowed platelet recovery, with adverse
sequelae in only 7% of patients.
Regarding our definition of complications, they were
thrombotic, embolic, or hemorrhagic events occurring in
patients receiving heparin therapy who had falling platelet
counts. The deaths related to the HIT syndrome were
those occurring in patients receiving heparin who devel-
oped thrombotic, embolic or hemorrhagic sequelae.
There were 16 deaths which we felt were not related to
HIT. One group received heparin to treat preexisting
thrombotic conditions, e.g., deep venous thrombosis. Of
those, the heparin was stopped promptly and the platelet
counts recovered to baseline. No new thrombotic, embol-
ic, or hemorrhagic complications occurred after the
heparin was discontinued, and there was no extension of
the thrombotic process. 
A second group received heparin on a prophylactic basis,
either before, during, or after surgery; they did not have
any thrombotic, embolic, or hemorrhagic complications as
a result of the heparin. These deaths were not caused by
HIT, and were attributed to the patient’s primary disease.
Some judgment was involved, I confess, but these were
our conclusions.
Dr. Edward V. Kinney (Louisville, Ky.). Could you
comment more on your experience with ReoPro? In my
practice, when this condition is seen during surgery, we
reverse the heparin and also try the ReoPro. The ReoPro
seems to have worked in the few cases I have had. Could
you expand on your experience?
Dr. Almeida. ReoPro, also known as c7E3, is the Fab
fragment of a monoclonal antibody to the GP IIb/IIIa
receptor on the platelet surface, and is thought to be a
potent inhibitor of platelet aggregation. We have yet to
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use ReoPro clinically. Our primary approach with these
patients is to use low molecular weight heparins if the
platelet aggregation studies do not show cross-reactivity
with standard unfractionated heparins. We have treated six
patients to date with enoxaparin, and one with dalteparin.
We have not found any patients that were cross-reactive to
both enoxaprin and dalteparin. We have not used ReoPro
clinically. We did present a paper last year on 21 patients
who had heparin antibodies, and ReoPro-inhibited
platelet aggregation in all of them. We will reserve use of
ReoPro if the above strategy fails.
Dr. William C. Krupski (Denver, Colo.). My under-
standing was that type I HIT was not antibody-mediated,
whereas IgM and IgG antibodies were implicated in type
II HIT. So were these patients all type II HIT, or were
these partly type I HIT? Could you elaborate?
Dr. Almeida. All 100 patients in this series had positive
platelet aggregation tests. Therefore, by definition, they all
possessed heparin-associated antiplatelet antibodies and
are type II.
Dr. Maciej Dryjski (Buffalo, N.Y.). Was the patient
with a complication treated with warfarin? The data from
Dr. Culton’s group in Canada indicates that patients with
heparin-induced thrombocytopenia should not be treated
with warfarin because the patients are hypercoagulable
and the warfarin initially decreases protein C level and
makes the patients more hypercoagulable. So my question
is did the patient with a complication receive warfarin?
Dr. Almeida. I think your question most applies to the
venous thrombotic complications. In those patients we
start heparin and Coumadin simultaneously. The heparin
is protective for the antithrombin-III, protein C, and pro-
tein S deficiencies, and one should not start Coumadin
alone. If the patients develop HIT during the oral antico-
agulation phase, the heparin is stopped. We start
antiplatelet therapy or a low molecular weight heparin (if
it is not cross-reative) to bridge the gap until adequate oral
anticoagulation is achieved.
Dr. Pavel Levy (Cleveland, Ohio). I would like to ask
two questions. First, platelet-induced aggregation, the test
you used and presented, is very specific. However, the test
is nonsensitive, and you mentioned several new tests, such
as 14C-serotonin release or P4 heparin enzyme-linked
immunosorbent assay (ELISA) test. I would like to know
which concentrations of heparin you used to challenge
patient plasma because challenging with an improper con-
centration may create a huge number of false-positive anti-
bodies.
Second, in your patients who had positive results, did
you try to double-check with a more sensitive test, such as
14C-serotonin release, which involves radioactive isotope,
or an immunologic test with P4 ELISA?
Dr. Almeida. Regarding the platelet aggregation test,
we use a concentration of 1 unit/ml of heparin. High-
dose heparin, 100 units/ml rules out false-positive results.
This is standard.
In our lab, we differentiate between weak-positive and
strong-positive platelet aggregation tests, which was not
addressed in this discussion. We are currently developing
an ELISA test and comparing the results with the platelet
aggregation test, which should aid in the understanding of
this disorder. However, these data are not presented in this
study.
